Is Evolus, Inc. (EOLS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 36.3% / 30% | 24.3% / 30% | 13.3% / 30% | 1.23% / 5% | ✗ NOT HALAL |
| DJIM | 36.3% / 33% | 24.3% / 33% | 13.3% / 33% | 1.23% / 5% | ✗ NOT HALAL |
| MSCI | 55.9% / 33% | 37.4% / 33% | 20.5% / 33% | 1.23% / 5% | ✗ NOT HALAL |
| S&P | 36.3% / 33% | 24.3% / 33% | 13.3% / 33% | 1.23% / 5% | ✗ NOT HALAL |
| FTSE | 55.9% / 33% | 37.4% / 33% | 20.5% / 50% | 1.23% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 66.3% | |
| Operating Margin | -0.3% | |
| Net Margin | -17.4% | |
| Return on Assets (ROA) | -10.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$42M |
| Free Cash Flow | -$51M |
| Total Debt | $155M |
| Current Ratio | 1.9 |
| Total Assets | $226M |
Price & Trading
| Last Close | $4.17 |
| 50-Day MA | $4.71 |
| 200-Day MA | $6.72 |
| Avg Volume | 1.3M |
| Beta | 1.0 |
|
52-Week Range
$3.98
| |
About Evolus, Inc. (EOLS)
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Evolus, Inc. (EOLS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Evolus, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Evolus, Inc.'s debt ratio?
Evolus, Inc.'s debt ratio is 36.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 55.9%.
What are Evolus, Inc.'s key financial metrics?
Evolus, Inc. has a market capitalization of $261M, and revenue of $297M. The company maintains a gross margin of 66.3% and a net margin of -17.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.